

Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

### **Policy**

Evolent Health considers **Breast Reconstruction Procedures and External Breast Prosthesis** medically necessary for the following indications:

#### **Breast Reconstruction:**

- Breast Reconstruction- All stages of breast reconstruction of the affected breast and procedures of the opposite breast to restore symmetry, including treatment of complications is considered medically necessary following a medically necessary mastectomy.
- 2. **Breast Implantation-** Breast implantation is covered when placed for reconstructive purposes following a mastectomy.
- 3. **Capsulectomy-** Capsulectomy is covered for complications of implant rupture or when other medical complications occur.
- 4. **Nipple Tattooing-** Nipple tattooing is covered when performed as a part of covered breast reconstruction procedures. This is the final stage of reconstruction, and may be delayed up to two years in some cases.

**Removal and/or Revision or Re-Implantation of Breast Implant** are covered, on a case-by-case basis, when medically necessary for any of the following conditions:

- 1. Implant failure, extrusion, leakage, rupture, or rejection
- 2. Interference with the diagnosis of breast cancer
- 3. Infection
- 4. Ischemia
- 5. Granuloma or siliconoma
- 6. Hematoma
- 7. Painful capsular contracture causing severe discomfort and disfigurement
- 8. Skin loss or extrusion of the prosthesis through the muscle area.
- 9. Trauma

#### **External Breast Prosthesis:**

- 1. Breast prosthesis is covered for a member who has had a mastectomy.
- An external breast prosthesis garment with mastectomy form (L8015) is covered for use in the
  post-operative period prior to a permanent breast prosthesis or as an alternative to a
  mastectomy bra and breast prosthesis.



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

3. A mastectomy bra (L8000) is covered when a member has a covered mastectomy form (L8020) or silicone (or equal) breast prosthesis (L8030), when the pocket of the bra is used to hold the form/prosthesis

#### Limitations

### **Breast Reconstruction:**

- Breast Reconstruction (breast implantation, removal, or revision) for any of the following conditions is considered not medically necessary and therefore not covered:
  - When a breast procedure is done for cosmetic purposes (i.e., to improve appearance shifting incorrect implant size, visible scars, uneven appearance, and wrinkling)
  - When done for anxiety over possible implant-associated disease
  - When done for changes in breast and/or nipple sensation
  - When the member has symptoms or a diagnosis of an auto-immune disorder, and there is no supporting documentation of a medical condition
  - For placement of breast implants which are not approved by the Food and Drug Administration (FDA).
- 2. Re-implantation of breast implants is not covered except when related to a cancer diagnosis.

### **External Breast Prosthesis:**

- 1. Mastectomy bra (without built in prosthesis)
  - There is no limit on mastectomy bras
- 2. Initial Prosthesis
  - Only one breast prosthesis per side for the useful lifetime of prosthesis. Two
    prostheses, one per each side, are allowed for members who have had bilateral
    mastectomies
- 3. Replacement Prosthesis: Replacement for the useful lifetime of a prosthesis (ordinary wear and tear) is as follows:
  - Silicone breast prostheses- two years
  - Nipple prosthesis- three months
  - Fabric, foam, or fiber filled breast prosthesis- six months.
  - Prosthesis of the same type can be replaced at any time if it is lost or is irreparably damaged (this does not include ordinary wear and tear).
  - Prosthesis of a different type can be replaced at any time if there is a change in the member's medical condition that necessitates a different type of item.
- 4. Not medically necessary and therefore not covered:



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

- Breast prosthesis (silicone or equal, with integral adhesive (L8031))
- Custom fabricated prosthesis (L8035, L8033)
- More than one breast prosthesis per side
- 5. Supplier:
  - A written signed and dated order must be received by the supplier before a claim is submitted.
- 6. Ordering and Delivery:
  - The supplier should not dispense more than a three month quantity at a time.
  - The beneficiary or caregiver must specifically request new items before they are dispensed. The supplier must not automatically dispense a quantity of items on a predetermined regular basis, even if the beneficiary has "authorized" this in advance.
  - Contact with the member regarding refills should take place no sooner than approximately seven days prior to the delivery/shipping date.
  - For subsequent deliveries of refills, the supplier should deliver the product no sooner than approximately five days prior to the end of usage for the current product.

### **Background**

Breast reconstruction may be an option for any woman receiving surgical treatment for breast cancer. All women undergoing breast cancer treatment should be educated about breast reconstructive options as adapted to their individual clinical situation. However, breast reconstruction should not interfere with the appropriate surgical management of the cancer. The process of breast reconstruction should not govern the timing or the scope of appropriate surgical management for this disease.

Breast reconstruction can be done immediately following mastectomy or delayed following the completion of cancer treatment (after mastectomy or lumpectomy surgery, as well as radiation therapy, chemotherapy or targeted therapies are given). In many cases, breast reconstruction involves a staged approach (delayed-immediate reconstruction).

The American Society of Plastic Surgeons (ASPS) has outlined the following as potential risk factors for post-operative complications:

- Smoking Smoking is associated with an increased risk of complications and an
  increased risk of reconstructive failure in members undergoing post-mastectomy
  expander/implant breast reconstruction. Patients should be informed of the
  increased risks and advised on smoking cessation as means to decrease
  surgical complications.
- Obesity A BMI of 25 or greater is associated with an increased risk of postoperative complications and reconstructive failure among patients



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

undergoing post-mastectomy expander/implant breast reconstruction. These risks are even higher among patients with a BMI greater than 30. Obese patients should be informed of their increased surgical risks with expander/implant reconstructions and advised on practical weight loss solutions.

 Diabetes - There is no evidence to indicate that diabetes is a significant independent risk factor for the development of either postoperative complications or reconstructive failure in patients undergoing post-mastectomy expander/implant breast reconstruction. However, this information should not deter surgeons from continuing to practice glycemic control in the peri-operative period for breast cancer patients.

#### Codes:

| CPT Codes / HCPCS Codes / ICD-10 Codes |   |  |
|--|---|--|
| Code                                   | Description   |  |
| Breast Reconstruction CPT Codes        |   |  |
| 11920                                  | Tattooing, Intradermal Introduction of Insoluble Opaque Pigments to Correct Color Defects of Skin, including Micropigmentation; 6.0 <sup>2</sup> cm or less   |  |
| 11921                                  | Tattooing, Intradermal Introduction of Insoluble Opaque Pigments to Correct Color Defects of Skin, including Micropigmentation, 6.1 to 20.02cm  |  |
| 11922                                  | Tattooing, Intradermal Introduction of Insoluble Opaque Pigments to Correct Color Defects of Skin, including Micropigmentation; each additional 20.0 <sup>2</sup> [List separately in addition to code for primary procedure] |  |
| 19316                                  | Mastopexy   |  |
| 11921                                  | Tattooing, Intradermal Introduction of Insoluble Opaque Pigments to Correct Color Defects of Skin, including Micropigmentation, 6.1 to 20.02cm  |  |
| 11922                                  | Tattooing, Intradermal Introduction of Insoluble Opaque Pigments to Correct Color Defects of Skin, including Micropigmentation; each additional 20.0 <sup>2</sup> [List separately in addition to code for primary procedure] |  |
| 19316                                  | Mastopexy   |  |
| 11921                                  | Tattooing, Intradermal Introduction of Insoluble Opaque Pigments to Correct Color Defects of Skin, including Micropigmentation, 6.1 to 20.02cm  |  |



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

| 19350   | Nipple/Areola Reconstruction  |  |
|---|---|--|
| 19357   | Breast Reconstruction, Immediate or Delayed, With Tissue Expander, Including Subsequent Expansion   |  |
| 19361   | Breast Reconstruction with Latissimus Dorsi Flap without Prosthetic Implant   |  |
| 19364   | Breast Reconstruction with Free Flap  |  |
| 19366   | Breast Reconstruction with Other Technique  |  |
| 19367   | Breast Reconstruction with Transverse Rectus Abdomins Myocutaneous Flap (Tram), Single Pedicle, Including Closure of Donor Site   |  |
| 19368   | Breast Reconstruction with Transverse Rectus Abdomins Myocutaneous Flap (Tram), Single Pedicle, Including Closure of Donor Site; With Microvascular Anastomosis (Supercharging) |  |
| 19369   | Breast Reconstruction with Transverse Rectus Abdomins Myocutaneous Flap (Tram), Double Pedicle, Including Closure of Donor Site   |  |
| 19380   | Revision of Reconstructed Breast  |  |
| 19396   | Preparation of Moulage for Custom Breast Implant  |  |
| External Breas  | st Prosthesis   |  |
| HCPCS codes covered if selection criteria are met (If Appropriate): |   |  |
| A4280   | Adhesive skin support attachment for use with external breast prosthesis, each  |  |
| L8000   | Breast prosthesis, mastectomy bra   |  |
| L8001   | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral   |  |
| L8002   | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral  |  |
| L8015   | External breast prosthesis garment, with mastectomy form, post mastectomy   |  |
| L8020   | Breast prosthesis, mastectomy form  |  |
| L8030   | Breast prosthesis, silicone or equal, without integral adhesive   |  |
| L8032   | Nipple prosthesis, reusable, any type, each   |  |
| L8039   | Breast prosthesis, not otherwise specified  |  |
| Non Covered HCPCS Codes   |   |  |



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

| L8031              | Breast prosthesis, silicone or equal, with integral adhesive            |
|--------------------|---|
| L0031              | Nipple prosthesis, custom fabricated, reusable, any material, any type, |
| L8033              | each  |
| L8035              | Custom breast prosthesis, post mastectomy, molded to patient model      |
| ICD-10 codes       |   |
| C44.501            | Unspecified malignant neoplasm of skin of breast                        |
| C44.591            | Other specified malignant neoplasm of skin of breast                    |
| C50.01-<br>C50.119 | Malignant neoplasm of nipple and areola                                 |
| C50.2-C50.219      | Malignant neoplasm of upper-inner quadrant of breast                    |
| C50.3-C50.319      | Malignant neoplasm of lower-inner quadrant of breast                    |
| C50.4-C50.419      | Malignant neoplasm of upper-outer quadrant of breast                    |
| C50.5-C50.519      | Malignant neoplasm of lower-outer quadrant of breast                    |
| C50.6-C50.619      | Malignant neoplasm of axillary tail of breast                           |
| C50.8-C50.819      | Malignant neoplasm of overlapping sites of breast                       |
| C50.9-C50.919      | Malignant neoplasm of breast of unspecified site                        |
| C79.81             | Secondary malignant neoplasm of breast                                  |
| D05.0-D05.02       | Lobular carcinoma in situ of breast                                     |
| D05.1-D05.12       | Intraductal carcinoma in situ of breast                                 |
| D05.8-D05.82       | Other specified type of carcinoma in situ of breast                     |
| D05.9-D05.92       | Unspecified type of carcinoma in situ of breast                         |
| D48.6              | Neoplasm of uncertain behavior of breast                                |
| D48.60             | Neoplasm of uncertain behavior of unspecified breast                    |
| D48.61             | Neoplasm of uncertain behavior of right breast                          |
| D48.62             | Neoplasm of uncertain behavior of left breast                           |
| 197.2              | Post-mastectomy lymphedema syndrome                                     |
| T85.49XA           | Other mechanical complication of breast prosthesis and implant, initial |
| T85.79XA           | Infection and inflammatory reaction due to other internal prosthetic    |
| T85.89XA           | Other specified complication of internal prosthetic devices, implants   |
| Z42.1              | Encounter for breast reconstruction following mastectomy                |



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

| Z44.30 | Encounter for fitting and adjustment of external breast prosthesis, unspecified breast |
|--------|--|
| Z44.31 | Encounter for fitting and adjustment of external right breast prosthesis               |
| Z44.32 | Encounter for fitting and adjustment of external left breast prosthesis                |
| Z85.3  | Personal history of malignant neoplasm of breast                                       |
| Z90.10 | Acquired absence of unspecified breast and nipple                                      |

#### References

- American Society of Plastic Surgeons (ASPS). Evidence-Based Clinical Practice Guideline: Breast Reconstruction with Expanders and Implants. Published: 3/2013. Available at: <a href="http://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/breast-reconstruction-expanders-with-implants-guidelines.pdf">http://www.plasticsurgery.org/Documents/medical-professionals/health-policy/evidence-practice/breast-reconstruction-expanders-with-implants-guidelines.pdf</a>
- Association of Breast Surgery (ABS)/British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS). Oncoplastic Breast Reconstruction. Guidelines for Best Practice. November 2012. Available at: <a href="http://www.bapras.org.uk/docs/default-source/commissioning-and-policy/final-oncoplastic-guidelines---healthcare-professionals.pdf?sfvrsn=0">http://www.bapras.org.uk/docs/default-source/commissioning-and-policy/final-oncoplastic-guidelines---healthcare-professionals.pdf?sfvrsn=0</a>
- 3. Breastcancer.org. When is Breast Reconstruction Done? Last modified March 7, 2019. http://www.breastcancer.org/treatment/surgery/reconstruction/when
- Center for Medicare and Medicaid Services (CMS). Local Coverage Article: No. A52478 - External Breast Prostheses (Contractor: CGS Administrators, LLC) Revision Effective Date: 01/01/2020.. https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=52478&ver=17&Date=&DocID=A52478&bc=ggAAAAgAAAAA&AA&



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020

- Cutress RI, Summerhayes C, Rainsburg R. Guidelines for oncoplastic breast reconstruction. Ann R Coll Surg Engl. 2013 Apr;95(3):161-2. doi: 10.1308/003588413X13511609957696. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165237/
- 8. D'Souza N, Darmanin G, Fedorowicz Z. Immediate versus delayed reconstruction following surgery for breast cancer (Review). Cochrane Datbase Syst Rev. 2011 Jul 6;(7):CD008674. doi: 10.1002/14651858.CD008674.pub2. http://www.ncbi.nlm.nih.gov/pubmed/21735435
- 9. Department of Health & Human Services (HHS). Agency for Healthcare Research and Quality (AHRQ). Statistical Brief #228: Breast Reconstruction Surgery for Mastectomy in Hospital Inpatient and Ambulatory Settings, 2009–2014, . October 2017 <a href="https://www.hcup-us.ahrq.gov/reports/statbriefs/sb228-Breast-Reconstruction-For-Mastectomy.pdf">https://www.hcup-us.ahrq.gov/reports/statbriefs/sb228-Breast-Reconstruction-For-Mastectomy.pdf</a>
- 10. Federal Act of 1998: Women's Health and Cancer Rights Act. Public Law 105-277. <a href="https://www.cms.gov/Regulations-and-Guidance/Health-Insurance-Reform/HealthInsReformforConsume/downloads/WHCRA\_Statute.pdf">https://www.cms.gov/Regulations-and-Guidance/Health-Insurance-Reform/HealthInsReformforConsume/downloads/WHCRA\_Statute.pdf</a>
- 11. Fentiman IS, Farhadi J. Breast reconstruction: à *la carte* not *table d'hote*. Cancer Treat Rev. 2012 Jun;38(4):269-271. doi: 10.1016/j.ctrv.2011.10.009. http://www.ncbi.nlm.nih.gov/pubmed/22116016
- 12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version: 3.2014 http://www.nccn.org/professionals/physician\_gls/pdf/breast.pdf

### Disclaimer:

Evolent Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Evolent Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Evolent Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.



Policy Number: MP-046 Last Review Date: 02/13/2020 Effective Date: 04/01/2020